RAPA-201 + carboplatin + paclitaxel

RAPA-201 + carboplatin + paclitaxel is an investigational combination therapy for solid tumors, particularly for PD-(L)1 refractory metastatic melanoma. **RAPA-201** is a novel adoptive cell therapy consisting of rapamycin-resistant, checkpoint-deficient, polyclonal Th1/Tc1 T cells generated via an ex vivo manufacturing platform that includes mTOR inhibition (via temsirolimus) and Th1/Tc1 polarization (via IFN-alpha). The therapy's key properties are anti-cancer Th1/Tc1 polarization, central memory phenotype for persistence, rapamycin-resistance for improved T cell fitness, reduced activation/reduced cytokine-release potential, and diminished expression of checkpoint receptors. This phenotype enables concurrent administration with cytotoxic chemotherapy, specifically outpatient **carboplatin** and **paclitaxel**, which are well-established antineoplastics (platinum compound and taxane, respectively) that disrupt DNA function (carboplatin) and inhibit microtubule function (paclitaxel) to induce apoptosis in rapidly dividing cancer cells[1][3][5][7].

Other names

Autologous Rapamycin-Resistant Th1/Tc1 CellsRAPA-201 plus CP regimenRAPA201 plus CP regimenRAPA 201 plus CP regimen